Thomas R.Cech, Chair
Dr. Cech is President of the Howard Hughes Medical Institute. He is also a Distinguished Professor at the University of Colorado, Boulder. He received his B.A. degree in chemistry from Grinnell College and his Ph.D. degree in chemistry from the University of California, Berkeley. His postdoctoral work in biology was conducted at the Massachusetts Institute of Technology. He is a member of the National Academy of Sciences and of the Institute of Medicine. Among the many honors he has received are the Lasker Award, the National Medal of Science, and the 1989 Nobel Prize in chemistry.
Dr. Eddy develops computer algorithms to decipher genomic DNA sequences. He is interested in finding genes that produce catalytic RNAs instead of proteins. Dr. Eddy is an HHMI Assistant Investigator and also Alvin Goldfarb Distinguished Professor of Computational Biology in the Department of Genetics at Washington University School of Medicine, St. Louis. He received his B.S. degree in biology from the California Institute of Technology and his Ph.D. degree in molecular biology from the University of Colorado at Boulder, under the direction of Larry Gold. He worked briefly in industry at NeXagen Pharmaceuticals, followed by postdoctoral work with Richard Durbin and John Sulston at the
MRC Laboratory of Molecular Biology in Cambridge, England, where he began to develop algorithms for computational analysis of genome sequences. He is a coauthor of the book Biological Sequence Analysis: Probabilistic Models of Proteins and Nucleic Acids.
David Eisenberg is an Investigator of the Howard Hughes Medical Institute and also serves as Director of the UCLA-DOE Laboratory of Structural Biology and Molecular Medicine at the University of California, Los Angeles. His work involves the determination and analysis of protein structures, with special interest in protein interactions. By combining information from structures, genome sequences, DNA microarrays, and from the scientific literature, Eisenberg is studying the networks of interacting proteins that control the lives of cells. He was elected to membership in the National Academy of Sciences in 1989. He received his Ph.D. from Oxford University, England.
Karen Hersey is the former Senior Counsel for Intellectual Property at the Massachusetts Institute of Technology in Cambridge, Massachusetts. Ms. Hersey joined MIT as a technology licensing attorney in 1980, just as technology transfer was becoming an important activity for U.S. research universities. In addition to licensing MIT’s patented technology she had primary responsibility for MIT’s early efforts to commercially license its computer-related technologies under the new U.S. Copyright law. In 1987, Ms. Hersey left MIT to take up the directorship of technology licensing at North Carolina State University in Raleigh. In 1990, Ms. Hersey returned to MIT as principal legal advisor on intellectual property matters and policy for MIT and with responsibility for advising on computer law and copyright-related issues. This responsibility led to an early interest in the problems universities confront in coping with use of copyrighted materials and the licensing of information products for educational and research use. Ms. Hersey now serves as an Advisor on Intellectual Property to MIT. She holds a bachelor’s degree from
Goucher College in Baltimore, Maryland and a law degree from Boston University and is a member of the Massachusetts and North Carolina Bars. An active member of the university technology-transfer community, she has chaired and participated in numerous workshops and seminars on technology transfer practice and intellectual property law, and is a past president of the Association of University Technology Managers. For the past five years, Ms. Hersey has served as a consultant to the Association of Research Libraries (ARL) on intellectual property and other legal issues confronting university libraries. She worked with the ARL to develop both a basic and advanced course for librarians covering copyright and the licensing of electronic resources. She participates as an instructor for both courses several times throughout the year.
Steven H.Holtzman is the President and Chief Executive Officer of Infinity Pharmaceuticals, Inc. Previously, he was the Chief Business Officer of Millennium Pharmaceuticals, Inc. in which role his responsibilities included licensing, intellectual property and corporate law, government relations, and public policy. Prior to joining Millennium, from 1986 to 1994, Mr. Holtzman was a founder and the first employee of DNX Corporation, the first commercial enterprise devoted to the development of biomedical and pharmaceutical applications of transgenic animal technology. In the early 1980s, Mr. Holtzman conceived of and was the founding Executive Director of the Ohio Edison Program, the nation’s first state government program directed to achieving economic development through funding young technology-based ventures and university/industry collaborative research and development efforts. In the late 1970s, Mr. Holtzman was an instructor and tutor in moral philosophy and the philosophy of language at Corpus Christi College, Oxford University, U.K. In 1995, Mr. Holtzman was a founding Co-Chair and is a current member of the Biotechnology Industry Organization (BIO) Bioethics Committee. In 1998, he served as a member of the Working Group of the Advisory Committee to the Director of the NIH on Access to Research Tools. In 1996, he was appointed by President Clinton as
the sole individual from the pharmaceutical or biotechnology industry to serve on the National Bioethics Advisory Commission, the principal advisory body to the President and Congress on ethical issues in the biomedical and life sciences. In late 1999, he was asked to serve a second term on the Commission. Since 1999, he has served as a Trustee of The Hastings Center for Bioethics. Mr. Holtzman received his B.A. in Philosophy from Michigan State University and his B.Phil. graduate degree in Philosophy from Oxford University, which he attended as a Rhodes Scholar. He is a frequent invited speaker at biotechnology and pharmaceutical industry conferences, NIH and NAS symposia, and business schools on the subjects of structuring alliances between biotechnology and pharmaceutical companies, biotechnology entrepreneur ship, bioethics, and patents and intellectual property protection in the life sciences.
George Poste is Chief Executive of Health Technology Networks, a consulting group specializing in the application of genomics technologies and computing in health care. From 1992 to 1999 he was Chief Science and Technology Officer and President, Research and Development of SmithKline Beecham (SB). During his tenure at SB he was associated with the successful registration of 29 drug, vaccine, and diagnostic products. Dr. Poste is Chairman of diaDexus and Structural GenomiX in California and serves on the Board of Directors of Maxygen, Illumina and Orchid Biosciences. He is also advisor to several venture capital funds. He is a fellow of Pembroke College Cambridge and Distinguished Fellow at the Hoover Institution and Stanford University. He is a member of the Defense Science Board of the U.S. Department of Defense and in this capacity he chairs the Task Force on Bioterrorism. He is also a member of the National Academy of Sciences Working Group on Defense Against Bioweapons.
Dr. Poste is a Board Certified Pathologist, a Fellow of the Royal Society, the National Academy of Great Britain and a Fellow of the
Academy of Medical Sciences. He has published over 350 scientific papers, coedited 15 books on cancer, biotechnology, and infectious diseases and serves on the editorial board of multiple technical journals. He is invited routinely to be the keynote speaker at a wide variety of academic, corporate, investment, and government meetings to discuss the impact of biotechnology and genetics on health care and the challenges posed by bioterrorism.
Natasha Raikhel is the Director of the newly organized Center for Plant Cell Biology (CEPCEB) within the Genomics Institute at the University of California at Riverside (UCR). She holds the Ernst and Helen Leibacher Endowed Chair in Plant Molecular, Cell Biology & Genetics, and is also a Distinguished Professor of Plant Cell Biology. Natasha Raikhel received her M.S. in Biology and her Ph.D. from the Institute of Cytology in Leningrad, USSR. She has served on numerous government and industry advisory boards and several editorial boards and was appointed Editor-in-Chief of Plant Physiology in May 2000. She was awarded the 2002 Senior Career Recognition Award by the Women in Cell Biology Committee of the American Society for Cell Biology (ASCB) and is recognized as one of the most highly cited researchers in the field of plant science. Prior to working at UCR, Natasha served as Professor in the DOE-Plant Research Laboratory at Michigan State University where she developed a research program to study the plant genes involved in nuclear and vacuolar protein sorting in Arabidopsis thaliana. Research in her laboratory is presently focused on understanding the fundamental principles of vacuolar biogenesis and protein trafficking through the secretory system and on elucidation of the components that mediate cell wall biosynthesis in plants. Her multidisciplinary approach utilizes a combination of cellular, molecular, genetic, proteomic, and genomic technologies. She has been working in this field for three decades and has guided many graduate and postdoctoral associates in their research.
Richard H.Scheller, Ph.D., joined Genentech in 2001 as senior vice president, Research. Prior to joining Genentech, Scheller served as professor of Molecular and Cellular Physiology and of Biological Sciences at Stanford University Medical Center and as an investigator at the Howard Hughes Medical Institute. Scheller received his first academic appointment to Stanford University in 1982. Scheller’s work in cell and molecular biology has earned him numerous awards including the 1997 National Academy of Sciences Award in Molecular Biology. He is a member of the Academy of Arts and Sciences and the National Academy of Sciences and is on the editorial board of several journals including Neuron, Molecular Biology of the Cell, and the Journal of Cell Biology. Scheller has served on numerous advisory boards including the National Advisory Mental Health Council of the National Institutes of Health. Scheller holds a doctorate in chemistry from the California Institute of Technology where he was also a postdoctoral fellow, Division of Biology. He was also a postdoctoral fellow at Columbia University, College of Physicians & Surgeons.
David B.Singer is the Chairman and Chief Executive of GeneSoft, a company focused on developing medical therapies to treat gene-mediated disease. Prior to joining GeneSoft, Mr. Singer was Senior Vice President and Chief Financial Officer of Heartport, Inc. He served as the founding President and Chief Executive Officer of Affymetrix, Inc. Mr. Singer also held business development and finance positions at Affymax NV and Baxter Healthcare Corporation. He is a director of Affymetrix and Corcept, Inc. Mr. Singer received his B.A. in History from Yale University and his M.B.A. from the Graduate School of Business at Stanford University. He is a Henry Crown Fellow of the Aspen Institute.
Mary Waltham, most recently President and Publisher for Nature and the Nature family of journals in the United States, and formerly Manag-
ing Director and Publisher of The Lancet in the UK, founded her own consulting company two years ago. Its purpose is to help international scientific, technical and medical publishers to confront the rapid change that the networked economy poses to their traditional business models, and to develop new opportunities to build publications that deliver outstanding scientific and economic value. She has worked at a senior level in science and medical publishing companies across a range of media, which includes textbooks, magazines, newsletters, journals, and open learning materials.